Novel Regenerative Medicine Approaches
To date, most human in vivo cell clinical and tissue engineering studies have employed adult stem and progenitor cells. However, initial clinical trials utilizing pluripotent stem cells are underway, and these cells may eventually emerge as a more tractable source of human material. iCell® and MyCell® products are being employed in a number of regenerative medicine applications:
- Regenerative medicine compound screening: Due to their biological relevance and compatibility with high-throughput screening paradigms, iCell and MyCell products enable identification of novel regenerative compounds
- Tissue engineering: iCell and MyCell products can be used to bioengineer implantable devices, reconstitute decellularized organs, and manufacture organs using 3D bioprinting
- Allogeneic and autologous cell applications: iPS cell technology may one day be used for allogeneic and autologous cell applications with the added benefit of being able to introduce a genetically corrected disease mutation in this context
CDI’s cellular reprogramming technologies, intellectual property portfolio, and manufacturing capabilities have broad applicability to the design, development, and manufacturing of future cell-based therapies. Translation of these therapeutic approaches to the clinic will require HLA-matched banks of iPS cells generated under good manufacturing practice (GMP) conditions, a project currently underway in a CDI partnership with Waisman Biomanufacturing.
Contact us to learn more about these exciting advances.